|
Profile Details
|
| YN Zhang |
|
Affiliations:
|
University of Toronto
Sun Yat-sen University Cancer Center,
Department of Nasopharyngeal Carcinoma
Unknown
|
| |
|
|
| , |
| Phone: |
| Fax: |
|
LinkedIN:
|
|
My Blogs:
|
| My Twitter Hashtags: |
| @AdrianaYZhang |
| |
| Age:
|
| Bio: |
| [1]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, P. R. China.[2]Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center. |
| |
| Specialty: |
| Cancer Biology, Cancer Immunotherapy |
| |
| Presented at Events Covering: |
|
| |
| Areas of Interest: |
|
| |
| Hobbies: |
|
| |
| General Comments: |
|
|
| BSN Rank:
457 / 2941
(What's this?) |
|
Accomplish Score: 162
|
|
Popularity Score: Unavailable
|
|
# in My Circle: 0
|
|
# in My Org(s): 15080
|
| We'll Post Your CV for Free! |
| |
| |
|
Speaking/Presenting-Abstract/Poster at Mtg: 0 (0 / 0)
|
|
| |
|
Honors and Awards: 0 (0 / 0)
|
|
| |
|
Clinical Trial Activity: 0 (0 / 0)
|
|
| |
|
Grant Support: 0 (0 / 0)
|
|
| |
|
Patents Pending: 0 (0 / 0)
|
|
| |
|
Journal - Editor/Reviewer: 0 (0 / 0)
|
|
| |
|
Peer Reviewed Papers, Books, Chapters: 27 (162 / 0)
|
-
We examined the benefits of the combination of anti-EGFR targeted treatment, cetuximab (CTX) or nimotuzumab (NTZ) and concurrent platinum-based chemoradiotherapy (CCRT) compared with CCRT alone in patients with stage II - IVb nasopharyngeal carcinoma (NPC). ()
-
Esophageal squamous cell carcinoma (ESCC) is a highly malignant tumor associated with a poor prognosis, and the molecular mechanisms underlying its formation and progression remain poorly understood. ()
-
Gallbladder cancer (GBC), highly aggressive form of cancer with an extremely poor prognosis, is the most common malignancy of the biliary tract. ()
|
| |
|
Pre/Non Reviewed Papers, Proceedings: 0 (0 / 0)
|
|
| |
|
Membership in Professional Societies: 0 (0 / 0)
|
|
| |
|
White Papers: 0 (0 / 0)
|
|
| |
| Registered on BiotechScienceNews: 0 |
|
How We Rank
